Safety review update of Revlimid and risk of developing new types of malignancies October 03, 2017Vol.40 No.08
Two Opdivo trials show three-year survival in patients with previously treated advanced NSCLC October 03, 2017Vol.40 No.08
Peter Pisters hits the right notes in town hall meeting at MD Anderson September 29, 2017Vol.43 No.36By Paul Goldberg
In draft, USPSTF recommends screening with hrHPV without cytology September 29, 2017Vol.43 No.36By Matthew Bin Han Ong
Guest Editorial A costly “rebranding” of an old drug comes with a 700% price increase September 29, 2017Vol.43 No.36By Jason Funaro, Henry S. Friedman and Mallika Weant
Lowy & Schiller at the Lasker Awards:The paradox of disease prevention, and how some scientists rise above their peers September 29, 2017Vol.43 No.36
NCI outlines research priorities in annual plan and bypass budget for FY19 September 22, 2017Vol.43 No.35By Matthew Bin Han Ong
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—But at FDA “Maybe” has meaning September 22, 2017Vol.43 No.35By Paul Goldberg
